Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses
The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world.
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.
Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also exist.
